Esperion Therapeutics, Inc. Share Price Today: Live Updates & Key Insights

Esperion Therapeutics, Inc. share price today is $2.57, up -1.92%. The stock opened at $2.6 against the previous close of $2.6, with an intraday high of $2.6 and low of $2.51.

Esperion Therapeutics, Inc. Share Price Chart

Esperion Therapeutics, Inc.

us-stock
To Invest in {{usstockname}}
us-stock

Esperion Therapeutics, Inc. Share Price Performance

$2.57 -0.0192(-1.92%) ESPR at 23 Mar 2026 12:55 PM Drug Manufacturers - Specialty & Generic
Lowest Today 2.51
Highest Today 2.6
Today’s Open 2.6
Prev. Close 2.6
52 Week High 4.18
52 Week Low 0.69
Day’s Range: Low 2.51 High 2.6
52-Week Range: Low 0.69 High 4.18
1 day return -
1 Week return -5.37
1 month return -23.38
3 month return -36.67
6 month return +2.2
1 year return +47.68
3 year return +75.6
5 year return -91.34
10 year return -

Esperion Therapeutics, Inc. Institutional Holdings

Vanguard Group Inc 6.09

BlackRock Inc 6.05

Two Seas Capital LP 4.85

Wasatch Advisors LP 3.85

Vanguard Total Stock Mkt Idx Inv 3.07

D. E. Shaw & Co LP 2.82

Orbimed Advisors, LLC 2.43

Geode Capital Management, LLC 2.34

iShares Russell 2000 ETF 2.33

Marshall Wace Asset Management Ltd 2.23

Two Sigma Investments LLC 1.93

State Street Corp 1.83

Wasatch Ultra Growth 1.80

Penderfund Capital Management Ltd 1.79

Pender Corporate Bond A 1.66

Morgan Stanley - Brokerage Accounts 1.65

AIGH Capital Management, LLC 1.63

Millennium Management LLC 1.60

Nuveen, LLC 1.47

Royce & Associates, LP 1.47

Two Sigma Advisers, LLC 1.43

Nuveen Quant Small Cap Equity R6 1.23

Wasatch Micro Cap 1.15

Biotech Growth Ord 1.14

Vanguard Institutional Extnd Mkt Idx Tr 1.06

Fidelity Small Cap Index 0.94

Renaissance Technologies Corp 0.90

JPMorgan Chase & Co 0.77

Northern Trust Corp 0.75

State Street® SPDR® S&P® PhrmctlsETF 0.65

State St Russell Sm/Mid Cp® Indx SL Cl I 0.56

iShares Russell 2000 Value ETF 0.55

Fidelity Extended Market Index 0.51

Royce Micro-Cap Trust 0.47

Vanguard Russell 2000 ETF 0.45

Royce Small-Cap Trust 0.38

Xtrackers MSCI World Swap ETF 1C 0.37

Vanguard Explorer Inv 0.34

Royce Small-Cap Composite 0.32

Royce Small-Cap Fund Invmt 0.32

Esperion Therapeutics, Inc. Market Status

Strong Buy: 2

Buy: 2

Hold: 2

Sell: 1

Strong Sell: 0

Esperion Therapeutics, Inc. Fundamentals

Market Cap 654.87 M

PB Ratio 98.4236

PE Ratio 0.0

Enterprise Value 739.25 M

Total Assets 465.89 M

Volume 5717057

Esperion Therapeutics, Inc. Company Financials

Annual Revenue FY23:102902000 102.9M, FY22:75475000 75.5M, FY21:78447000 78.4M, FY20:227547000 227.5M, FY19:148364000 148.4M

Annual Profit FY23:66927000 66.9M, FY22:48508000 48.5M, FY21:64230000 64.2M, FY20:225155000 225.2M, FY19:148364000 148.4M

Annual Net worth FY23:-208391000 -208.4M, FY22:-287817000 -287.8M, FY21:-318824000 -318.8M, FY20:-166189000 -166.2M, FY19:-109022000 -109.0M

Quarterly Revenue Q3/2025:87309000 87.3M, Q2/2025:82385000 82.4M, Q1/2025:64995000 65.0M, Q3/2024:51632000 51.6M, Q2/2024:73834000 73.8M

Quarterly Profit Q3/2025:31889000 31.9M, Q2/2025:53842000 53.8M, Q1/2025:33457000 33.5M, Q3/2024:34346000 34.3M, Q2/2024:58215000 58.2M

Quarterly Net worth Q3/2025:-31333000 -31.3M, Q2/2025:-12725000 -12.7M, Q1/2025:-40455000 -40.5M, Q3/2024:-29524000 -29.5M, Q2/2024:-61925000 -61.9M

About Esperion Therapeutics, Inc. & investment objective

Company Information Esperion Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company's marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia cardiovascular disease who require additional lowering of LDL-C. Its products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. It has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was formerly known as HDL Therapeutics, Inc. and changed its name to Esperion Therapeutics, Inc. in May 2008. The company was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Organisation Drug Manufacturers - Specialty & Generic

Employees 294

Industry Drug Manufacturers - Specialty & Generic

CEO Mr. Sheldon L. Koenig M.B.A.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

Esperion Therapeutics, Inc. FAQs

What is the share price of Esperion Therapeutics, Inc. today?

The current share price of Esperion Therapeutics, Inc. is $2.57.

Can I buy Esperion Therapeutics, Inc. shares in India?

Yes, Indian investors can buy Esperion Therapeutics, Inc. shares by opening an international trading and demat account with Motilal Oswal.

How to buy Esperion Therapeutics, Inc. shares in India?

You can easily invest in Esperion Therapeutics, Inc. shares from India by:

Can I buy fractional shares of Esperion Therapeutics, Inc.?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Esperion Therapeutics, Inc.?

Esperion Therapeutics, Inc. has a market cap of $654.87 M.

In which sector does Esperion Therapeutics, Inc. belong?

Esperion Therapeutics, Inc. operates in the Drug Manufacturers - Specialty & Generic sector.

What documents are required to invest in Esperion Therapeutics, Inc. stocks?

To invest, you typically need:

What is the PE and PB ratio of Esperion Therapeutics, Inc.?

The PE ratio of Esperion Therapeutics, Inc. is N/A and the PB ratio is 98.42.